Triplet Combination Demonstrates Encouraging Anti-Tumor Activity and Tolerability in Recurrent Platinum-Sensitive Ovarian Cancer WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 17, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 25, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of
Broad Anti-Leukemia Activity in Relapsed/Refractory and Frontline AML Presented in Oral Session Recommended Phase 2 Dose Well-Tolerated; Determination of Optimal Venclexta Duration Ongoing in Separate Cohorts WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 10, 2022-- ImmunoGen, Inc.
Pivekimab Triplet Demonstrates Encouraging CR, Composite CR, and MRD Negativity Rates; Broad Anti-Leukemia Activity Observed Across All Molecular Subsets Evaluated Pivekimab-Containing Triplet Well-Tolerated with Manageable Safety Profile Data Support Continued Development of Triplet; Enrollment
FORWARD I Did Not Meet Primary Endpoint of Progression-Free Survival; Promising Efficacy Results Seen in Folate Receptor Alpha (FRα) High Patients Favorable Tolerability and Differentiated Safety Profile Observed with Mirvetuximab Monotherapy Compared to Chemotherapy Exploratory Analyses
Trial Met Primary Endpoint with Confirmed Objective Response Rate of 32.4%, including 5 Complete Responses; Updated Median Duration of Response of 6.9 Months Mirvetuximab Demonstrated Meaningful Anti-Tumor Activity, Consistent Safety, and Favorable Tolerability in FRα-High Platinum-Resistant
With a Confirmed Overall Response Rate of 64% and Favorable Tolerability in Patients with High FRα Expression, Combination Demonstrates Encouraging Outcomes Relative to Available Regimens WALTHAM, Mass. --(BUSINESS WIRE)--May 29, 2020-- ImmunoGen, Inc.
Preliminary Data Demonstrate Favorable Safety Profile and Encouraging Activity in Heavily Pretreated Patients with Ovarian Cancer WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 20, 2018-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment
FORWARD II Triplet Combination Demonstrates Encouraging Anti-Tumor Activity Preliminary Findings Support Ongoing Study in Platinum-Sensitive Patients WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 29, 2019-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug
Triplet Data Demonstrating Manageable Safety Profile and Promising Anti-Leukemia Activity Highlighted in Oral Presentation Expansion Cohorts in Relapsed and Frontline AML Planned Data for IMGN632 in Three Frontline BPDCN Patients Also Presented in Poster Presentation Showing Clinical Complete